HC Wainwright Reiterates “Buy” Rating for Vigil Neuroscience (NASDAQ:VIGL)

Vigil Neuroscience (NASDAQ:VIGL)‘s stock had its “buy” rating reissued by HC Wainwright in a report released on Thursday,Benzinga reports. They currently have a $17.00 price objective on the stock.

Other equities analysts have also issued research reports about the stock. William Blair initiated coverage on shares of Vigil Neuroscience in a report on Wednesday, December 4th. They issued an “outperform” rating on the stock. JMP Securities reiterated a “market outperform” rating and set a $22.00 price objective on shares of Vigil Neuroscience in a report on Tuesday, November 26th. Finally, Wedbush upped their price objective on shares of Vigil Neuroscience from $23.00 to $24.00 and gave the company an “outperform” rating in a report on Friday, November 8th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $19.75.

Vigil Neuroscience Stock Up 33.1 %

Shares of NASDAQ VIGL traded up $0.67 during midday trading on Thursday, reaching $2.70. 28,103,026 shares of the company were exchanged, compared to its average volume of 2,166,916. The stock’s 50-day moving average price is $2.12 and its 200-day moving average price is $3.12. The stock has a market cap of $110.42 million, a P/E ratio of -1.29 and a beta of 1.76. Vigil Neuroscience has a one year low of $1.49 and a one year high of $6.06.

Vigil Neuroscience (NASDAQ:VIGL) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.08. On average, equities research analysts anticipate that Vigil Neuroscience will post -2.07 EPS for the current year.

Institutional Investors Weigh In On Vigil Neuroscience

A number of institutional investors have recently added to or reduced their stakes in VIGL. Point72 Asia Singapore Pte. Ltd. bought a new stake in Vigil Neuroscience in the 2nd quarter worth about $87,000. Renaissance Technologies LLC grew its stake in Vigil Neuroscience by 19.2% in the 2nd quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock valued at $286,000 after buying an additional 11,536 shares in the last quarter. Walleye Capital LLC boosted its holdings in Vigil Neuroscience by 334.4% in the 3rd quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock valued at $407,000 after purchasing an additional 92,217 shares during the period. Verition Fund Management LLC bought a new position in Vigil Neuroscience in the 3rd quarter valued at $442,000. Finally, Geode Capital Management LLC boosted its holdings in Vigil Neuroscience by 41.9% in the 3rd quarter. Geode Capital Management LLC now owns 226,083 shares of the company’s stock valued at $769,000 after purchasing an additional 66,712 shares during the period. 83.64% of the stock is owned by institutional investors.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.